Novo Nordisk A S annual net profit margin
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Net Profit Margin Growth & History (NVO)
Novo Nordisk A S's net profit margin was 33.14% for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 33.14% | −1.63 pp |
| 2024 | 2024-12-31 | 34.78% | −1.25 pp |
| 2023 | 2023-12-31 | 36.03% | +4.65 pp |
| 2022 | 2022-12-31 | 31.38% | −2.54 pp |
| 2021 | 2021-12-31 | 33.92% | +0.72 pp |
| 2020 | 2020-12-31 | 33.19% | +1.27 pp |
| 2019 | 2019-12-31 | 31.92% | — |
Novo Nordisk A S quarterly net profit margin
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 26.74% | −7.74 pp |
| Q1 2026 | 2026-03-31 | 50.15% | +12.97 pp |
| Q4 2025 | 2025-12-31 | 33.98% | +1.03 pp |
| Q3 2025 | 2025-09-30 | 26.68% | −11.60 pp |
| Q2 2025 | 2025-06-30 | 34.48% | +5.02 pp |
| Q1 2025 | 2025-03-31 | 37.18% | −1.70 pp |
| Q4 2024 | 2024-12-31 | 32.95% | — |
| Q3 2024 | 2024-09-30 | 38.28% | — |
| Q2 2024 | 2024-06-30 | 29.46% | — |
| Q1 2024 | 2024-03-31 | 38.88% | — |
Novo Nordisk A S net profit margin trends
Over the last five fiscal years, Novo Nordisk A S's net profit margin decreased from 33.19% to 33.14%, a change of −0.05 percentage points. The latest reported quarter, Q2 2026, shows 26.74%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...